Portfolio News
Sofinnova Crossover
Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors
GenSight Biologics announces today the success of its previously announced capital increase. The transaction was led by Arix Bioscience plc (LON: ARIX), Invus, and Sofinnova Partners.
October 22, 2020 12:30 AM Eastern Daylight Time
PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today the success of its previously announced capital increase. The transaction was led by Arix Bioscience plc (LON: ARIX), Invus and Sofinnova Partners.
The Company has issued 5,954,650 new ordinary shares with a nominal value of €0.025 each (the "New Shares"), for total gross proceeds of approximately €25 million by means of an accelerated bookbuilding process to the benefit of categories of persons (the "Reserved Offering"). The book was oversubscribed, based on demand from new and existing investors.
The issue price of the New Shares is €4.20 per share, representing a 12.5% discount to the volume weighted average of the share prices on Euronext Paris for the last five trading sessions preceding the date on which the issuance price is set (ie., October 15, 16, 19, 20 and 21, 2020), in accordance with the 19th resolution of the combined annual general meeting of shareholders of the Company held on April 29, 2020.
Related News
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in atraumatic sutureless peripheral nerve repair
Moon Surgical Expands Leadership Team to Accelerate Commercial Growth Across U.S. and Europe
Micropep and Corteva announce multi-year research collaboration to advance sustainable biocontrol solutions
Gradient Denervation Technologies announces acceptance into FDA’s Total Product Life Cycle Advisory Program for development of its pulmonary artery denervation system
AFYREN begins new phase of industrial strategy as first plant AFYREN NEOXY achieves continuous production